MMP9 and ADNP Gene Expressions in Secondary Bone Metastasis of Locally Advanced Nasopharyngeal Cancer
Keywords:
MMP-9, ADNP, nasopharyngeal cancer, secondary bone metastasisAbstract
Background: Nasopharyngeal cancer (NPC) is a malignancy of the nasopharyngeal mucosal epithelium. Primary and secondary metastases in nasopharyngeal cancer are generally prevalent in the bones. Gene expression plays a critical role in regulating fundamental cellular processes in cancer cells, including metastasis. Methods: A total of 29 patients with non-metastatic NPC were included in the study. Results: The mean age of the participants was 48.45±9.98 years old. Most participants were male (75.9%). More than half of the participants had T4 and N2, 52.7% and 51.0% respectively). Secondary metastasis was observed in 9 of the 29 participants within two years. Patients with secondary metastases had a higher proportion of T4 (7/9) and N2 (4/9) disease. Bone was the first site of secondary metastasis (6/9 patients). The median time to secondary bone metastasis was 14.0 (6.8-21.2) months. Based on the differential expression gene (DEG) analysis, the MMP9 gene was upregulated 12.50 (4.18–37.40), adjusted p <0.01, and the ADNP gene was downregulated 0.141 (0.04–0.43), adjusted p 0.04, among patients with secondary bone metastasis. Conclusion: Bones are the first site of metastasis, with a time to metastasis of 14.0 (6.8-21,2) months. MMP9 was upregulated, and ANDP was downregulated in patients with bone metastasis compared to those without metastasis.References
Akervall J, Kurnit DM, Adams M, et al. Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck. Acta Otolaryngol. 2004;124(7):851–7.
Salehiniya H, Mohammadian M, Mohammadian-Hafshejani A, Mahdavifar N. Nasopharyngeal cancer in the world: Epidemiology, incidence, mortality, and risk factors. WCRJ. 2018;5(1):e1046.
Faisal HH. Analisis kesintasan dan faktor yang berperan pada pasien kanker nasofaring di departemen tht rsupn dr. Cipto Mangunkusumo [Tesis]. Jakarta: Universitas Indonesia; 2017.
Adham M, Kurniawan AN, Muhtadi AI, et al. Nasopharyngeal carcinoma in Indonesia: Epidemiology, incidence, signs, and symptoms at presentation. Chin J Cancer. 2012;31(4):185–96.
Guo LL, Wang HY, Zheng LS, et al. Metastasis of nasopharyngeal carcinoma: What we know and do not know. Vis Cancer Med. 2021;2:4.
Luo DH, Li JX, Guo WP, et al. The map of bone metastasis in nasopharyngeal carcinoma: A real-world study. Cancer Medicine. 2023;12(17):17660-70.
Liao W, Tian M, Chen N. Characteristic and novel therapeutic strategies of nasopharyngeal carcinoma with synchronous metastasis. Cancer Manag Res. 2019;11:8431-42.
Wang N, Wu QL, Fang Y, et al. Expression of chemokine receptor CXCR4 in nasopharyngeal carcinoma: Pattern of expression and correlation with clinical outcome. J Transl Med. 2005;3:26.
Resteghini C, Alfieri S, Quattrone P, et al. Rank expression in ebv positive nasopharyngeal carcinoma metastasis: A ready-to-treat target? Oncotarget. 2017;8(56):96184-9.
Wang MH, Zhou XM, Zhang MY, et al. BMP2 promotes proliferation and invasion of nasopharyngeal carcinoma cells via mtorc1 pathway. Aging (Albany, NY). 2017;9(4):1326-40.
Qin H, Wang R, Wei G, et al. Overexpression of osteopontin promotes cell proliferation and migration in human nasopharyngeal carcinoma and is associated with poor prognosis. Eur Arch Otorhinolaryngol. 2018;275(2):525-34.
Ke L, Xiang Y, Guo X, et al. C-src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/AKT signaling pathway: A new and promising target for NPC. Oncotarget. 2016;7(19):28340-55.
Ferlier T, Coulouarn C. Regulation of gene expression in cancer: an overview. Cells. 2022;11(24):4058.
Singh KP, Miaskowski C, Dhruva AA, Flowers E, Kober KM. Mechanisms and measurement of changes in gene expression. Biol Res Nurs. 2018;20(4):369-82.
Tsang HF, Xue VW, Koh SP, Chiu YM, Ng LP, Wong SC. Nanostring, a novel digital color-coded barcode technology: Current and future applications in molecular diagnostics. Expert Rev Mol Diagn. 2017;17(1):95-103.
Nanostring Technologies. N Counter advanced analysis 2.0 user manual 2018 [cited 2023 4 August]. Available from: https://nanostring.com/wp-content/uploads/MAN-10030-03_nCounter_Advanced_Analysis_2.0_User_Manual.pdf.
Guo Y, Chen JX, Yang S, et al. Selection of reliable reference genes for gene expression study in nasopharyngeal carcinoma. Acta pharmacologica Sinica. 2010;31(11):1487–94.
Pan W-R, Suami H, Corlett RJ, Ashton MW. Lymphatic drainage of the nasal fossae and nasopharynx: Preliminary anatomical and radiological study with clinical implications. Head & Neck. 2009;31(1):52–7.
Ho FCH, Tham IWK, Earnest A, Lee KM, Lu JJ. Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: A meta-analysis of clinical evidence. BMC Cancer. 2012;12(1):98-110.
Qu W, Li S, Zhang M, Qiao Q. Pattern and prognosis of distant metastases in nasopharyngeal carcinoma: A large-population retrospective analysis. Cancer Med. 2020;9(17):6147–58.
Guo LL, Wang HY, Zheng LS, et al. Metastasis of nasopharyngeal carcinoma: What we know and do not know. Vis Cancer Med. 2021;2:4.
Shen L, Dong J, Li S, et al. M1 stage subdivision and treatment outcome of patients with bone-only metastasis of nasopharyngeal carcinoma. The Oncologist. 2015;20(3):291–8.
Chan J, Pilch B, Kuo T, Wenig B, Lee A. Tumours of the nasopharynx. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World health organization pathology and Genetics of Head and neck tumours. Lyon: IARC Press; 2005. p. 83–97.
Grisanti S, Bianchi S, Locati LD, et al. Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. PLOS ONE. 2019;14(3):e0213934.
Pisani P, Airoldi M, Allais A, et al. Metastatic disease in head & neck oncology. Acta Otorhinolaryngologica Italica: organo ufficiale della Società Italiana di Otorinolaringologia e Chirurgia cervico-facciale. 2020;40(1):S1-S86.
Cahyanur R, Irawan C, Lisnawati L, et al. CXCL8, MMP1, MMP2, and FN1 gene expression and tumor extension in nasopharyngeal cancer patients: A cross-sectional study. Acta Med Indones. 2023;55(3):261-8.
Cahyanur. R, Irawan C, Rachmadi L, et al. Primary bone metastasis in nasopharyngeal cancer: A study on CXCR4, RANK, RANKL, BMP2, OPN, PTHLH, IL-8, and SRC genes expression [Dissertation]. Jakarta: Universitas Indonesia; 2024.
Zhang S, Xiao X, Yi Y, et al. Tumor initiation and early tumorigenesis: Molecular mechanisms and interventional targets. Signal Transduction and Targeted Therapy. 2024;9(1):149.
Pego ER, Fernández I, Núñez MJ. Molecular basis of the effect of MMP-9 on the prostate bone metastasis: A review. Urologic Oncology: Seminars and Original Investigations. 2018;36(6):272-82.
Christensen J, Shastri VP. Matrix-metalloproteinase-9 is cleaved and activated by cathepsin K. BMC Research Notes. 2015;8(1):322.
Lan YY, Yeh TH, Lin WH, et al. Epstein-Barr virus zta upregulates matrix metalloproteinases 3 and 9 that synergistically promote cell invasion in vitro. PLOS ONE. 2013;8(2):e56121.
Sun X, Peng X, Cao Y, Zhou Y, Sun Y. ADNP promotes neural differentiation by modulating wnt/β-catenin signaling. Nat Commun. 2020;11(1):2984.
Karagoz K, Mehta GA, Khella CA, Khanna P, Gatza ML. Integrative proteogenomic analyses of human tumours identify adnp as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis. EBioMedicine. 2019;50:191-202.
Blaj C, Bringmann A, Schmidt EM, et al. Adnp is a therapeutically inducible repressor of Wnt signaling in colorectal cancer. Clin Cancer Res. 2017;23(11):2769-80.
Rangel R, Guzman-Rojas L, Kodama T, et al. Identification of new tumor suppressor genes in triple-negative breast cancer. Cancer Res. 2017;77(15):4089-101.
Wang X, Peng H, Zhang G, et al. Adnp is associated with immune infiltration and radiosensitivity in hepatocellular carcinoma for predicting the prognosis. BMC Med Genomics. 2023;16(1):178.
Zhu S, Xu Z, Zeng Y, et al. Adnp upregulation promotes bladder cancer cell proliferation via the akt pathway. Front Oncol. 2020;10:491129.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Rahmat Cahyanur, Cosphiadi Irawan, Lisnawati Rachmadi, Marlinda Adham, Achmad Fauzi Kamal, Achmad Rusdan Handoyo Utomo, Mardiah Suci Hardianti, Thariqah Salamah, Muchtaruddin Mansyur
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
